A *Saccharomyces cerevisiae* Assay System to Investigate Ligand/AdipoR1 Interactions That Lead to Cellular Signaling

Mustapha Aouida1,a, Kangchang Kim2, Abdul Rajjak Shaikh3, Jose M. Pardo4, Jörg Eppinger3, Dae-Jin Yun2, Ray A. Bressan1,5, Meena L. Narasimhan1,a,b

1 Plant Stress Genomics Research Center, King Abdullah University of Science and Technology, Thuwal, Kingdom of Saudi Arabia, 2 Division of Applied Life Science (Brain Korea 21 Program), Plant Molecular Biology and Biotechnology Research Center, Gyeongsang National University, Jinju, Republic of Korea, 3 KAUST Catalysis Center, Division of Physical Sciences and Engineering, King Abdullah University of Science and Technology, Thuwal, Kingdom of Saudi Arabia, 4 Instituto de Recursos Naturales y Agrobiologia, Consejo Superior de Investigaciones Científicas, Sevilla, Spain, 5 Department of Horticulture and Landscape Architecture, Purdue University, West Lafayette, Indiana, United States of America

Abstract

Adiponectin is a mammalian hormone that exerts anti-diabetic, anti-cancer and cardioprotective effects through interaction with its major ubiquitously expressed plasma membrane localized receptors, AdipoR1 and AdipoR2. Here, we report a *Saccharomyces cerevisiae* based method for investigating agonist-AdipoR interactions that is amenable for high-throughput scale-up and can be used to study both AdipoRs separately. Agonist-AdipoR1 interactions are detected using a split firefly luciferase assay based on reconstitution of firefly luciferase (Luc) activity due to juxtaposition of its N- and C-terminal fragments, NLuc and CLuc, by ligand induced interaction of the chimeric proteins CLuc-AdipoR1 and APPL1-NLuc (adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif 1-NLuc) in a *S. cerevisiae* strain lacking the yeast homolog of AdipoRs (Izh2p). The assay monitors the earliest known step in the adiponectin-AdipoR anti-diabetic signaling cascade. We demonstrate that reconstituted Luc activity can be detected in colonies or cells using a CCD camera and quantified in cell suspensions using a microplate reader. AdipoR1-APPL1 interaction occurs in absence of ligand but can be stimulated specifically by agonists such as adiponectin and the tobacco protein osmotin that was shown to have AdipoR-dependent adiponectin-like biological activity in mammalian cells. To further validate this assay, we have modeled the three dimensional structures of receptor-ligand complexes of membrane-embedded AdipoR1 with cyclic peptides derived from osmotin or osmotin-like plant proteins. We demonstrate that the calculated AdipoR1-peptide binding energies correlate with the peptides’ ability to behave as AdipoR1 agonists in the split luciferase assay. Further, we demonstrate agonist-AdipoR dependent activation of protein kinase A (PKA) signaling and AMP activated protein kinase (AMPK) phosphorylation in *S. cerevisiae*, which are homologous to important mammalian adiponectin-AdipoR1 signaling pathways. This system should facilitate the development of therapeutic inventions targeting adiponectin and/or AdipoR physiology.

Introduction

Adiponectin is a protein hormone secreted by adipose tissue in mammals and it plays crucial roles in the regulation of glucose and lipid metabolism, inflammation and oxidative stress [1,2,3,4]. Missense mutations in the adiponectin gene are associated with the incidence of type 2 diabetes [5,6]. Reduced serum concentrations of adiponectin correlate with obesity, type 2 diabetes, cardiovascular risk, as well as increased risk of several types of cancer [7,8,9]. Administration of recombinant adiponectin or genetic overexpression of adiponectin in rodent models has therapeutic effects in diabetes, ischemic cardiac injury and in colon cancer [10,11,12,13,14,15,16]. These findings triggered the great attention adiponectin receives today and support the development of therapeutic agents based on adiponectin replacement.

Adiponectin is a 30 kDa protein that consists of a N-terminal collagen domain and a C-terminal globular C1q domain [3]. It is a highly abundant serum protein. In serum, adiponectin...
glycosylated and exists as a trimer, hexamer and higher order oligomers. The globular C1q domain can be released by proteolysis and is biologically active, but it is not found in significant amounts in serum. Several in vitro and in vivo studies have shown that two proteins, AdipoR1 and AdipoR2, serve as the major receptors for adiponectin [11,17]. AdipoRs and G-protein coupled receptors (GPCRs) share a 7-transmembrane pass topology but are functionally distinct. Also, as members of the PAQR (Pogrestin and AdipoQ Receptor) family, AdipoRs have a cytosolic N-terminus and external C-terminus, which is the opposite orientation of classical GPCRs [18].

The signaling pathways activated by adiponectin depend on (a) the molecular form (glycosylation status and degree of oligomerization) of adiponectin, since the different forms show selectivity for the two AdipoRs, (b) the relative abundance of the two AdipoRs, since the receptors show selectivity for downstream signaling, and (c) the target tissue [17,19,20,21]. For example, AdipoR1 acts as a high affinity receptor for global adiponectin and has a lower affinity for full length adiponectin, while AdipoR2 possesses medium affinity for these adiponectin variants [21]. In skeletal muscle cells, the anti-diabetic effect of adiponectin is mediated by stimulation of glucose oxidation via the AMPK pathway and by increase of fatty acid oxidation via the AMPK and peroxisome proliferator-activated receptor (PPAR) pathways [3,20]. In the liver, the anti-diabetic action of adiponectin is linked to increased gluconeogenesis via AMPK activation, whereas stimulation of fatty acid oxidation, decrease of inflammation and increased insulin sensitivity are achieved via the PPAR pathway [17]. In vascular endothelial cells adiponectin has an anti-inflammatory effect due to enhanced nitric oxide production, suppression of oxidative stress and suppression of inflammatory signaling [22]. These anti-inflammatory effects of adiponectin in the vascular endothelium have been explained by AMPK activation and a cyclic AMP-protein kinase A (cAMP-PKA) pathway. In cardiomyocytes, the protective effects of adiponectin are mediated by AMPK and cyclo-oxygenase 2 signaling [22]. AdipoR1 exerts the major effect in mediating the anti-diabetic action of adiponectin in skeletal muscle whereas both AdipoRs have major roles in its anti-diabetic actions in the liver [17,20].

These studies suggest that there is considerable value in the identification of AdipoR agonists as therapeutic agents. It is also evident that identification of signaling pathways specifically activated by an agonist and one of the AdipoRs would provide valuable information for the design of therapeutic agents. We reasoned that a system designed to perform function studies of AdipoRs and analyses of the influence of ligand sequence similarity between the corresponding subunits. S. cerevisiae and mammalian AMPKs play similar roles in balancing energy metabolism (Figure 1).

First, reactions and regulatory steps of glucose and lipid metabolism are very similar in yeast and mammalian cells [23]. Energy metabolism in S. cerevisiae is connected to glucose and lipid metabolism via the same pathways that exist in mammalian cells. Importantly, AMPKs of mammals and S. cerevisiae have similar subunit structure [24,25]. S. cerevisiae and mammalian AMPKs can be cross-activated by their respective upstream kinases due to sequence similarity between the corresponding subunits. S. cerevisiae and mammalian AMPKs play similar roles in balancing energy demand with energy supply from carbohydrate and lipid metabolism (Figure 1).

Second, although four S. cerevisiae proteins Izh1p, Izh2p, Izh3p, and Izh4p share deduced sequence similarity with mammalian AdipoRs, adiponectin is unable to stimulate intracellular signaling that leads to repression of ferroxidase (FER3), a gene involved in metal ion homeostasis in yeast, unless AdipoR1 or AdipoR2 are expressed [26]. These results demonstrate that it is possible to examine signaling from AdipoR1 and AdipoR2 separately in yeast.

Third, activation of PKA and regulation of gene expression by AMPK due to adiponectin-AdipoR interaction contribute to the beneficial effects of adiponectin in mammalian systems [3,22,24]. Signaling from Izh2p and AdipoR2 has also been shown to activate the PKA pathway and affect AMPK-dependent gene expression in S. cerevisiae (Figure 1). Izh2p and AdipoRs negatively regulate expression of genes involved in metal ion homeostasis through both PKA and AMPK in S. cerevisiae, via a CCCTC promoter element [26,27]. It should be noted activation of PKA has an opposite effect on the cellular reactive oxygen species (ROS) content in mammalian and yeast systems. Activation of the AdipoR-PKA pathway decreases cellular content of ROS in mammalian vascular endothelial cells [22]. On the other hand, activation of the IZH2-PKA pathway signaling has been shown to suppress transcription from the CCCTC stress-responsive promoter element (STRE) that is found on some oxidative stress inducible genes, which increases the cellular content of ROS in S. cerevisiae [27,28,29].

However, adiponectin-AdipoR dependent activation of AMPK via increased phosphorylation of the S. cerevisiae AMPKα subunit, Snf1p, has not yet been described. Since this activating phosphorylation plays a key role in the anti-diabetic actions of adiponectin in skeletal muscle and liver, and in the cardioprotective actions of adiponectin [3,19,22], evidence for a central element in yeast adiponectin-AdipoR signaling is missing. Hence, we set out to establish S. cerevisiae systems to (a) accurately report agonist-AdipoR interactions and (b) report the agonist-AdipoR dependent activation of signaling pathways similar to those known to be important for controlling diabetes or cardiovascular function in mammals. Here we report a split firefly luciferase based assay for investigating ligand-AdipoR1 interactions. We further show that activation of yeast AMPK by phosphorylation of its α subunit, Snf1p, can be observed in response to agonist-AdipoR1 or agonist-AdipoR2 interaction in S. cerevisiae and demonstrate agonist-AdipoR dependent suppression of oxidative stress signaling via activation of the PKA pathway in S. cerevisiae. The split luciferase assays can be adapted easily for multiwell arrays suitable for high-throughput platforms using automated replating and mechanized washing. Hence our S. cerevisiae based system promises to be an effective tool for the identification of novel pharmacologically active AdipoR agonists. It will also facilitate structure-function studies of AdipoRs and analyses of the influence of ligand structure on ligand-AdipoR interactions, which could serve as basis for intelligent agonist synthesis.

Materials and Methods

Strains and Growth Media

S. cerevisiae strains were derivatives of BWG1-7a MATa ade1-100 ura3-52 leu2-3,112 his3-112 GAL4 [30] or BY4741 [MATa his3Δ1 leu2Δ0 met5Δ0 ura3Δ0] (from Dr. D. Ramotar, Universite de Montreal). Yeast cells were grown at 30°C in either YPD (1% yeast extract, 2% peptone, 2% dextrose) or selective synthetic complete medium [0.67% yeast nitrogen base without amino acids, 2% dextrose, pH 5.7, supplemented with appropriate dropout mix (Clontech, Mountain View, CA, USA)]. For control of gene expression under the GAL promoter, dextrose was substituted by raffinose and/or galactose to a final concentration of 2%. Yeast cells were transformed by the lithium acetate method [31]. Targeted insertion or deletion mutations of IZH2, SNF1, and

PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e65454
SIP3 were made using the KanMX4 gene as described [32] and confirmed by PCR.

Construction of Plasmids

Construction of the plasmid pSTRE-lacZ (LEU2) has been described earlier [29]. The entire coding regions of the human adiponectin receptors AdipoR1 and AdipoR2 and the Adaptor protein containing Pleckstrin homology domain, Phosphotyrosine binding domain and Leucine zipper motif 1 (APPL1) were obtained by RT-PCR from total RNA isolated from MCF-7 breast cancer cells. The sequences of the primers used in the constructions described below are shown in Table S1. The PCR products obtained using primer pairs AdipoR1-F-Spe1/AdipoR1-R-Cla1 and AdipoR2-F-Spe1/AdipoR2-R-Cla1 were inserted into an intermediate vector by TA cloning, then excised with SpeI and ClaI and inserted into the corresponding sites of p426-GPD for construction of the plasmids p426-GPD-AdipoR1 and p426-GPD-AdipoR2. APPL1 coding sequence was amplified using primers APPL1-F-KpnI-SpeI and APPL1-R-SalI-1. The PCR product was cut with KpnI and SalI and inserted between the cassette and the expression cassette in the p426-GPD-AdipoR1 and p426-GPD-AdipoR2 plasmids.

Figure 1. Summary of AdipoR-mediated signaling pathways in mammalian cells and IZH2-mediated signaling pathways in S. cerevisiae cells. (A) The components of the AdipoR1 signaling pathway of mammalian cells are shown in black font and their S. cerevisiae homologs, if known are shown in red font. In mammalian cells, adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif 1 (APPL1) interacts directly with AdipoR1. Interaction of adiponectin (ADPN) with AdipoR1 stimulates AdipoR1-APPL1 interaction. This results in release of Ca$^{2+}$ from the ER and also increases export of LKB1 kinase from the nucleus. Influx of extracellular Ca$^{2+}$ to the cytosol is also stimulated by adiponectin, although the mechanism by which this occurs remains to be clarified. Increase in cytosolic Ca$^{2+}$ concentration activates Ca$^{2+}$/calmodulin-dependent protein kinase (CaMKK) which in turn activates AMPK, AMPKβ, AMPKα, and AMPKγ subunits. The details of this pathway are not clear yet. Activation of AMPK is required for many of the anti-diabetic and anti-atherosclerotic effects of adiponectin. In vascular endothelial cells, interaction of AdipoR1 with adiponectin activates protein kinase A (PKA) which has the effect of lowering accumulation of reactive oxygen species (ROS) and thereby reducing inflammation. (B) Subunit structure of S. cerevisiae AMPK (ScAMPK). Like mammalian AMPK, ScAMPK is a trimer composed of an α, β, and γ subunit. The genes encoding the β subunit isoforms as well as the sole α and γ subunits are indicated. (C) Components of the IZH2-mediated signaling pathways in S. cerevisiae are shown in red font. Interaction of IZH2 (homolog of AdipoRs) with osmotin (OSM) activates PKA via a RAS2-cAMP pathway. Overexpression of IZH2, overexpression of AdipoR1, treatment of S. cerevisiae cells expressing AdipoR1 with adiponectin and treatment of S. cerevisiae cells expressing various levels of IZH2 with thaumatin (THN), a homolog of osmotin, has been shown to activate PKA by increasing cellular ceramidase activity. Activation of PKA leads to decreased transcription from a stress responsive promoter element (STRE) and increased cellular ROS content. Activated PKA promotes export of ScAMPK from the nucleus which leads to decreased transcription from the ferroxidase (FET3) promoter. Activated PKA also represses FET3 transcription via the stress-responsive transcription factors MSN2/4. Mutational analyses show that genes encoding the ScAMPKβ subunit Sip3, the LKB1-like protein Sak1, the ScAMPKγ subunit Snf4 and the ScAMPKα subunit Snf3 are components of the pathway leading from IZH2 (or AdipoR1) to FET3 repression in S. cerevisiae.
the corresponding sites in vector 3S-NLac [33], yielding the chimeric 3S-APPL1-NLac construct. The APPL1-NLac fragment was then excised by digestion with SpeI and PstI and ligated into p425-GPD cut with the same enzymes to generate the p425-GPD-APPL1-NLac construct. Construction of pESC-CLuc-AdipoR1 and pESC-CLuc-AdipoR2 was also performed in two steps. CLuc was first introduced downstream of the GAL1 promoter in pESC-URA and then AdipoR1 or AdipoR2 were fused in-frame to CLuc. CLuc was amplified by PCR from the vector 3S-CLuc using primers CLuc-F-BamHI and CLuc-R-XhoI-AseI-HindIII. The PCR products were digested with BamHI and HindIII and cloned into the cognate sites of pESC-URA, yielding pESC-CLuc. Then the coding sequence of AdipoR1 and AdipoR2 were amplified by RT-PCR from the total RNA using the primer pairs AdipoR1-F-Xhol/AdipoR1-HindIII and AdipoR2-F-Xhol/AdipoR2-HindIII, respectively. The PCR products were digested with XhoI and HindIII and ligated into pESC-CLuc digested with the same enzymes to yield pESC-CLuc-AdipoR1 and pESC-CLuc-AdipoR2. pESC-CLuc-AdipoR1-APPL1-NLuc that contains GAL1-CLuc-AdipoR1 and GAL10-APPL1-NLuc in the same vector was constructed as follows. APPL1-NLuc was amplified from p425-GPD-APPL1-NLuc by PCR using the primer pair APPL1-F-NotI/NLuc -R-ClaI. The PCR product was digested with NotI and ClaI inserted into the cognate sites pESC-CLuc-AdipoR1 yielding pESC-CLuc-AdipoR1-APPL1-NLuc. All constructs were verified by sequencing.

The pYES-EGFP-AdipoR1 and pYES-EGFP-AdipoR2 plasmids that contained EGFP fused in-frame to the N-terminus of AdipoR1 and AdipoR2, respectively, were constructed as follows. The entire AdipoR1 and AdipoR2 ORFs were amplified by PCR from cDNA isolated from human THP-1 cells using the AdipoR1-F-NotI/NLuc -R-ClaI and AdipoR2-F-Xhol/AdipoR2-HindIII primers. The PCR products were digested with NotI and ClaI inserted into the cognate sites pESC-CLuc-AdipoR1 yielding pESC-CLuc-AdipoR1-APPL1-NLuc. All constructs were verified by sequencing.

Osmotin, Adiponectin and Peptides

Osmotin was purified to homogeneity from suspension cultured salt-adapted tobacco cells as described before [34]. Osmotin was stored as sterile solution in ultrapure water (HPLC grade). The osmotin preparation was determined to be over 99% homogenous by 2D polyacrylamide gel electrophoresis and by mass spectrometry. The IC50 (amount of osmotin that reduces growth by 50%) was determined by literature methods [35] and ranged between 4–8 μg/mL for the osmotin batches used in this study. Osmotin and adiponectin were quantified using the BCA Protein Assay Reagent ( Pierce, Rockford, IL, USA) using bovine serum albumin as standard. Unless specified otherwise, the pure recombinant Escherichia coli expressed N-terminal (His)12-tagged full length human adiponectin used in these studies was the gift of Dr. A. Sharkhau (KAUST, Saudi Arabia) or Dr. I. Sokolchik (Purdue University, USA). The biological activity of endotoxin-free full length human adiponectin batches used in this work was verified by measuring its ability to induce apoptosis of MCF-7 breast cancer cells or THP-1 monocytic leukemia cells [36,37]. Bacterially expressed human globular adiponectin (Biovendecor, Candler, NC, USA) and bacterially expressed recombinant full length human adiponectin (Biovision, Mountain View, CA, USA or Genway, San Diego, CA, USA) were used in some tests as indicated in the figures. The synthetic cyclic peptides, OSMpep and ZMTNpep, used in this work were purchased from American Peptide Company (Sunnyvale, CA, USA). Peptide purity was 98% and they were dissolved in water at concentration of 1 mg/mL.

Gene Expression Analysis by RT-PCR

Total RNA was prepared using the RiboPure-Yeast extraction kit (Ambion, Grant Island, NY, USA) from 3 mL of overnight culture grown in selective minimal medium and genomic DNA contamination was eliminated using the TURBO DNA-free kit (Ambion). cDNA was synthesized from total RNA (2 μg) using M-MLV reverse transcriptase (Invitrogen, Grant Island, NY, USA). The PCR primers used to amplify the target genes are listed in Table S2. The PCR program was 2 min at 95°C followed by 25 cycles of 1 min of denaturation at 94°C, 2 min of annealing at a temperature specific for each gene fragment (e.g. 54°C for ACT1 fragment) and 4 min of extension at 72°C. This was followed by extension at 72°C for 7 min. PCR products were analyzed on a 1% agarose gel.

Luminescence Imaging and Luciferase Activity Measurement

Cultures were grown overnight at 30°C in selective minimal with 2% raffinose as carbon source. Cells were collected by 5 min centrifugation at 6000 rpm, and cell pellets were washed with the same medium but lacking sugar. Cells were resuspended at A600 nm of 0.4 in selective minimal medium supplemented with galactose or a galactose-raffinose mixture (2% sugar) as carbon source and grown at 30°C for 16 h. The cultures were adjusted to A600 nm of 0.4 and aliquots (100 μL) were centrifuged for 1 min at 16,000×g. Cell pellets were resuspended in 100 μL of 0.1 M Na citrate buffer pH 3.0 containing 1 mM D-luciferin (Gold Biotechnology, St. Louis, MO, USA), and transferred to individual wells of a 96-well plate (Nunc White polystyrene). The assay plate was incubated for 5 min at room temperature in the darkness before luminescence imaging under a CCD camera (Lumazone, Princeton Instruments, USA) or for luciferase activity measurement using a TEGAN Ultra 96microplate reader. A unit of luciferase activity was calculated as the luminescence value of sample minus the luminescence value of blank solvent.

Measurement of β-Galactosidase Activity

For determination of β-galactosidase activity, cells were grown in selective minimal medium to A600 nm of 0.4, resuspended in YPD at A600 nm of 6.0 (ca. 107 cells/mL). Cells (1 mL) were then mixed with water (0.2 mL) containing various amounts of osmotin and incubated at 30°C with occasional mixing. Cells were collected at the end of the incubation period by centrifugation and resuspended in the same volume of ice cold Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 mM 2-mercaptoethanol, pH 7.0). The A600 nm of the cell suspension was measured and adjusted to 1.0 by the addition of more ice cold Z buffer. Cells (0.1 mL) were mixed with Z buffer (0.9 mL), chloroform (0.1 mL) and 0.1% SDS (5 μL), vortexed for 10 sec and then subjected to three freeze-thaw cycles (liquid nitrogen 30 sec—37°C 90 sec). The suspension of broken cells was warmed to 28°C and enzyme activity was initiated by addition of o-nitrophenyl-β-D-galactopyranoside (0.2 mL of 4 mg/mL solution). The reaction was allowed to proceed at 28°C for various time periods and then terminated by addition of 1 M sodium carbonate solution (0.5 mL). The suspension was clarified by centrifugation and the absorbance of the supernatant was measured at 420 nm. One unit of β-galactosidase activity was defined as 1000 X ΔA420 nm/min/A600 nm:
Immunoblot Analysis

For examining the expression of EGFP-tagged AdipoRs, cultures were grown as described under ‘Luminescence Imaging and Luciferase Activity Measurement’. Total protein extracts were prepared from cells grown on 2% galactose in yeast extraction buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 5% glycerol, 1 mM each of EDTA, phenylmethylsulfonyl fluoride, and diithiothreitol, 0.5 µg/mL each of pepstatin, aprotinin, and leupeptin) as previously described [38]. One hundred µg of membrane proteins were fractionated by 10% SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (Immobilon P, Millipore). EGFP was visualized by the ECL method (GE Healthcare, UK) using monoclonal antibody to GFP as primary antibody (Clontech, Mountain View, CA, USA) and horseradish peroxidase-conjugated secondary antibody.

For examining the phosphorylation of S. cerevisiae AMPKα subunit (Snf1p), cells were grown and treated with osmotin (or adiponectin) exactly as described under ‘Measurement of β-Galactosidase Activity’. Treated cells were broken by trichloroacetic acid (TCA) protein extraction method and cell-free extracts were fractionated by SDS-PAGE on 10% polyacrylamide gels. After transfer to nitrocellulose membranes (Millipore, Billerica, MA, USA), phospho-Snf1p was detected by the ECL method (Thermo, Rockford, IL, USA) using monoclonal antibody to phospho-AMPKα (Thr172) as the primary antibody (Cell Signaling, Danvers, MA, USA) and goat anti-rabbit horseradish peroxidase as secondary antibody. Band intensities were measured on Luminescent Image Analyzer LAS-4000 with Multi Gauge Signaling, Danvers, MA, USA, and EGFP (26 kDa) was confirmed by Western blot analysis of cell-free extracts with an anti-GFP antibody.

Confocal Microscopy

Cells expressing EGFP-tagged receptors were grown as described under ‘Luminescence Imaging and Luciferase Activity Measurement’. Cells grown in 2% galactose were fixed by incubating in 0.1% formaldehyde at room temperature for 25 min. After washing 3 X with 0.1 M sodium phosphate buffer containing 0.137 M NaCl (pH 6.5), cells were re-suspended in the same buffer and stained for 5 minutes with DAPI (0.5 µg/mL) in the dark at room temperature. Cells were examined and photographed under a confocal laser-scanning microscope (Zeiss LSM 510 META).

Computational Studies

Details on homology modeling, MD simulations and docking studies are given in Methods S1. In brief, the 3D-homology model of human AdipoR1 was built for amino acids 135–364 with the Schrodinger suite 2011 using archaeal (Natronomonas pharaonis) phototaxis protein rhodopsin II (PDB id: 1GU8) as template structure [39]. The resulting homology model of AdipoR1 was embedded in 1,2-dipalmitoylphosphatidylcholine (DPPC) membrane and subjected to minimization and MD relaxation [GROMACS 4.5.5 software package and GROMOS53a6 force field [40]. The 3D structure of the globular domain of human adiponectin (residues 105–254) was built using the YASARA structure molecular modeling package [41] using a murine isoform (PDB id: 1C3H) as template [42]. Energy minimization and MD relaxation was performed using Yasara scripts. For docking of protein and peptide/AdipoR1 complexes PATCHDOCK and FireDock were used. Resulting complexes were energy minimized and analyzed following MD simulation (GROMACS).

Results

Adiponectin Receptors are Expressed on the Surface of Yeast Cells

We first confirmed the correct localization of AdipoRs in plasma membranes of S. cerevisiae by fluorescence microscopy using EGFP-AdipoR fusion proteins. As shown in Figure 2, cells of the wild type S. cerevisiae strain BY4741 transformed with a multicopy plasmid expressing EGFP under the GAL promoter displayed a diffuse intracellular fluorescence suggestive of cytoplasmic localization. However, cells expressing EGFP-AdipoR1 or EGFP-AdipoR2 from the same plasmid vector exhibited a strong fluorescence on the surface that was absent in control cells expressing only EGFP, suggesting plasma membrane localization of the recombinant AdipoRs. Fluorescence was also observed in vesicles that resembled the pre-vacuolar compartment, possibly due to degradation of AdipoR1 and AdipoR2 in the vacuole. Expression of EGFP-AdipoR1 (65 kDa), EGFP-AdipoR2 (65 kDa) and EGFP (26 kDa) was confirmed by Western blot analysis of cell-free extracts with an anti-GFP antibody.

Strategy for Reporting Adiponectin-AdipoR1 Interaction

In mammalian cells, APPL1 directly interacts with the intracellular N-terminal sequence of AdipoR1 [43,44]. AdipoR1-APPL1 interaction is stimulated by adiponectin and it triggers the activation of AMPK in mammalian cells (Figure 1). APPL1 also interacts with AdipoR2 [43], but downstream signaling resulting from the AdipoR2-APPL1 interaction is not well-understood. Since ligand-stimulated AdipoR1-APPL1 interaction is the earliest known step in the adiponectin-AdipoR signaling cascade, we decided to use it as the basis for our S. cerevisiae-based assay targeting AdipoR1-ligand interactions. We selected the split-luciferase bimolecular complementation assay as reporter system for AdipoR1-APPL1 contacts, since it is a well-established method for studying protein-protein interactions in mammalian, plant and S. cerevisiae cells [45,46,47]. Accordingly, a chimeric gene encoding human APPL1 fused in-frame at its C-terminus to firefly luciferase fragment 2-416 (NLuc) was cloned into the multiple cloning site 1 of the vector pESC-URA to yield the control plasmid pESC-URA-APPL1-NLuc (Figure 3A). This plasmid allows the expression of APPL1-NLuc from the GAL10 promoter. Similarly, a second chimeric gene encoding firefly luciferase fragment 398–550 (CLuc) fused to the N-terminus of AdipoR1, and inserted into the multiple cloning site 2 of the vector pESC-URA, yielded the control plasmid pESC-URA-CLuc-AdipoR1 (Figure 3A). This plasmid allows the expression of CLuc-AdipoR1 from the GAL1 promoter. Both chimeric proteins, CLuc-AdipoR1 and APPL1-NLuc, contained a linker between the two fragments to confer some mobility to the luciferase domains thus facilitating reconstitution of luciferase activity. The test plasmid pESC-URA-CLuc-AdipoR1-APPL1-NLuc for simultaneous expression of both the chimeric proteins, APPL1-NLuc and CLuc-AdipoR1, was then constructed from these two control plasmids using gap repair cloning. All plasmids were transformed into S. cerevisiae strain BY4741 for expression test.

Proof-Of-Concept: Receptor Level-Dependent Reconstitution of Luciferase Activity

It has been reported that overexpression of IEH2 and AdipoR1 can activate downstream signaling leading to suppression of FET3 promoter-dependent transcription even in absence of a ligand (Figure 1) [26,48]. Therefore, to prove that the bi-molecular complementation assay based on split-luciferase was functional, we performed luminescence imaging of colonies after full induction of
the GAL1 and GAL10 promoters by 2% galactose in the growth media. It can be seen (Figure 3B) that upon application of the substrate, D-luciferin, only transformants carrying the test plasmid pESC-URA-CLuc-AdipoR1-APPL1-NLuc exhibited luminescence whereas transformants carrying either the vector pESC-URA, or the control plasmids pESC-URA-CLuc-AdipoR1 and pESC-URA-APPL1-NLuc did not. Next, we studied whether the obtained reporter gene activity is proportional to the expression levels of AdipoR1 and APPL1. First, expression levels of both AdipoR1 and APPL1 in the pESC-URA-CLuc-AdipoR1-APPL1-NLuc transformant were confirmed to increase in proportion to the galactose concentration in the growth medium (Figure 4A). Next, assays performed in microtiter plates showed that luciferase activity in pESC-URA-CLuc-AdipoR1-APPL1-NLuc transformants increased as a function of galactose concentration in the medium (Figure 4B). Again, no significant luciferase activity could be detected in controls that expressed only one or none of the interaction partners (Figure 4B). These results indicated that the reporter activity directly correlated with the amounts of the interacting partners.

Among the IZH family proteins, Izh2p has most homology with AdipoRs (about 32% amino acid sequence identity). Therefore, we examined whether IZH2 maybe interfering with the AdipoR1-APPL1 interaction resulting in a reduced luciferase reporter activity. As shown in Figure 4C, luciferase activity was increased significantly by inactivation of IZH2. This effect was observed in cells grown in 1%, 1.5% and 2% galactose, indicating that Izh2p competes with AdipoR1 for binding to APPL1. The putative ortholog of APPL1 in S. cerevisiae is Sip3p and genetic evidence supports a role of SIPS in IZH2 signaling (Figure 1) [26]. However, inactivation of SIPS did not significantly increase luciferase activity indicating that Sip3p does not compete with APPL1 for AdipoR1 binding (Figure 4C).

Demonstration of Adiponectin- and Osmotin-Induced Increase in Luciferase Activity

Next, we tested whether incubation of galactose-induced cells with AdipoR1 ligands further stimulated luciferase reporter activity. In addition to adiponectin, we also used osmotin as a test ligand. Osmotin is a tobacco defense protein that has been shown to be a structural and functional homolog of adiponectin [29]. Specifically, osmotin stimulates AMPKα phosphorylation in an AdipoR-dependent manner in murine skeletal muscle cells and also stimulates IZH2-dependent intracellular signaling in S. cerevisiae [29]. While direct binding of adiponectin and osmotin to AdipoRs has not yet been observed experimentally, homology model based docking results confirm that complexes of both proteins with the extracellular surface of AdipoR1 are energetically favorable [49].

Luciferase activity of galactose-induced pESC-URA-CLuc-AdipoR1-APPL1-NLuc carrying cells of strain BY4741 was increased upon additional incubation with either globular...
adiponectin, full length adiponectin from two sources or osmotin, compared to incubation with solvent (1/8 X PBS) (Figures 5A and S1). On the other hand, the luciferase activity remained constant upon additional incubation with the negative control protein Bovine Serum Albumin (BSA) compared to incubation with solvent (Figure 5A), indicating that the luciferase activity was stimulated specifically by the predicted ligands of AdipoR1 [49]. These results also agree with experiments showing that AdipoR1-signaling is initiated by bacterially expressed full length adiponectin, globular adiponectin and osmotin [21], [29]. Ligand-induced increase in luciferase activity was observed only upon achieving a detectable signal even in absence of added ligand, requiring cells to be induced with 1–2% galactose (Figures 5A and S1). Next, we quantified luciferase activity in cells induced with different galactose concentrations after incubation with a range of osmotin concentrations (Figure 5B). The results confirmed that ligand-induced luciferase activity was observed only in cells that were grown at or above 1% galactose. Luciferase activity was approximately the same at 1% and 1.5% galactose and also did not vary within the range of osmotin concentrations tested (3.2–12.8 μM).

**Evaluation of Thaumatin Like Protein (TLP)-Based Peptides as Ligands of AdipoR1**

A nine residue cyclic osmotin-derived peptide (OSMpep, Table 1) was predicted to interact with AdipoR1 on the basis of molecular modeling studies and then shown to induce AdipoR1-
dependent intracellular signaling in mammalian cells [49]. This peptide is structurally stable and rigid and the simulation of its interaction with AdipoR1 predicted that it binds to the same region of AdipoR1 as adiponectin [49]. Proteins with sequence, structure and serological similarity to osmotin are ubiquitous in plants and are referred to as thaumatin-like proteins (TLPs). We hypothesized that the homologs of OSMpep from other TLPs such as soybean P21, banana TLP, thaumatin, kiwi Act d2 and corn zeamatin may bind as well or better to AdipoR1 as OSMpep. These TLPs were selected as the source of peptide sequences for the following reasons: (i) the structures of osmotin, banana TLP, thaumatin and zeamatin have been determined by X-ray crystallography (Table 1), so many of the selected peptides are confirmed to exist in a similar structural context in all the TLPs; (ii) thaumatin and osmotin have been shown to stimulate IZH2-dependent signaling in S. cerevisiae and many TLPs have antifungal activity, rendering it possible that some of these peptides might have biological activity [29,48,50,51]. We tested our hypothesis using a molecular modeling approach. Building on the strategy of Miele et al., [49], we were able to create a membrane embedded AdipoR1 homology model covering amino acids 135-364 of human AdipoR1. The 11 additional C-terminal amino acids in our model compared to that of Miele et al., [49] provided an extended 7th transmembrane helix which reached up to the receptor’s binding site. This homology model served as basis for docking studies of adiponectin and osmotin on AdipoR1 and to predict TLP peptide-AdipoR1 interactions and possible TLP binding (Figures S2 and S3). Shortly after we had finished our molecular modeling studies, a crystal structure of an engineered single-chain trimer human adiponectin globular domain was published (PDB id: 4DOU) [58]. The structure is in excellent agreement with our homology model for human globular adiponectin with a nearly identical geometry of the binding site residues (Figure S3G). Our homology model and engineered trimeric templates [52] lead to nearly identical docking results. All ligand/AdipoR1 interactions predicted by our model took place at the same overall binding site, which was formed by a central cleft between the 3 extracellular loops and extended to the C-terminal 7th transmembrane helix of AdipoR1. Our membrane embedded model gave clear indications, identifying AdipoR1
residues that can participate in binding. For example, one top scoring complex for the docking of osmotin to the membrane free receptor model [49] was omitted in our membrane embedded model, because part of the interaction took place on the membrane-covered surface of AdipoR1. Although our membrane embedded model and the membrane free receptor model [49] predict similar overall architectures of complexes and binding sites, we found clear differences in the residues involved in ligand/AdipoR1 interactions (see Figures S4 and S5 for details). Compared to the earlier model [49], the interacting region of AdipoR1 in our model was generally shorter on loop 1, shifted to toward the C-terminus on loop 3, and extended on loop 5. We also found a weak C-terminal interaction. However amino acids G354 and V355 of AdipoR1, which are predicted to be interacting residues in the model of Miele et al., [49] were found to be membrane embedded and hence not accessible in our model. Overall, extension of helix 7 and membrane embedding led to important differences in the prediction of ligand binding sites on AdipoR1.

The docking scores received for the tested TLP peptides suggest that the osmotin derived peptide (OSMpep) has the highest binding affinity to AdipoR1, while the zeamatin derived peptide (ZMTNpep) is the weakest binding ligand (Table 1). However, OSMpep and ZMTNpep interact in a very similar way with the

Figure 5. The AdipoR1 ligands, adiponectin and osmotin, induce increase in Luc reporter activity. Cells of strain BY4741 carrying pESC-URA-Cluc-AdipoR1-APPL1-NLuc were grown for 16 h at 30°C in selective minimal medium at the indicated galactose concentrations, treated for 4 h at 30°C with the indicated test compounds and then assayed for Luc activity. (A) Imaging of Luc activity. (B) Quantitative measurement of Luc activity as a function of osmotin concentration. A representative image of relative Luc activity at the different osmotin concentrations is shown for each galactose concentration. Data represent the means ± SD from three experiments with triplicate samples. For each galactose concentration, significant differences by a Student’s t-test between osmotin treated samples and untreated control are indicated by asterisks. Symbols: PBS, 1/8 X PBS; f-ADPN, bacterially expressed full length adiponectin; BSA, bovine serum albumin, OSM, osmotin; g-ADPN, bacterially expressed globular adiponectin; **, p<0.01; ***, p<0.001.

doi:10.1371/journal.pone.0065454.g005
AdipoR1 binding site, which also strongly resembles the AdipoR1-osmotin interaction (Figures 6, S3D, S4 and S6). We tested the model prediction experimentally using the split luciferase assay described above. The assay was performed in the izh2Δ mutant to avoid possible interference by Izhp. As shown in Figure 6D, the luminescence intensity of pESC-URA-CLac-AdipoR1-APPL1-Nlac transformed cells treated with osmotin or OSMpep was significantly greater than that of cells treated with PBS or equivalent concentration of ZMTNpep. Thus, computational predictions and experimental results are in agreement, which suggests that the split luciferase assay is able to discriminate between good and poor ligands of AdipoR1.

**Osmotin Signaling Mediated by Adiponectin Receptors**

**Results in Phosphorylation of Snf1p**

AMPKs have conserved structure and are essential for control of energy metabolism in yeast, plants and mammals [24,25]. The catalytic activity of AMPKs is upregulated by phosphorylation of a conserved Thr residue on the catalytic α subunit. Phosphorylation of murine AMPKα subunit on this conserved Thr172 by adiponectin or osmotin is abrogated by silencing the expression of adiponectin receptors in cultured murine myotubes [29]. Snf1p is the sole AMPKα subunit present in the *S. cerevisiae* proteome and it is activated by phosphorylation at the conserved threonine, Thr210, in response to glucose starvation or stress [25]. To examine whether osmotin and adiponectin can stimulate AdipoR1- or AdipoR2-dependent phosphorylation of Snf1p at Thr210, we determined the cellular content of phospho-Snf1p in osmotin- or adiponectin-treated cells of strain BWG1-7a that were expressing *AdipoR1* or *AdipoR2* constitutively from a multicopy plasmid (Figure 7). No significant increase in phospho-Snf1p levels were observed in empty vector, pAdipoR1 or pAdipoR2 transformants after osmotin or adiponectin treatments. This suggested that IZH2 could be interfering with AdipoR1-dependent Snf1-activation signaling, just as it interferes with APPL1-dependent AdipoR1 signaling (Figure 4C). Therefore we repeated this experiment using an izh2Δ mutant of strain BWG1-7a. We found the cellular content of Thr210-phosphorylated Snf1p was unaffected by osmotin or adiponectin treatments in an izh2Δ mutant transformed with the empty vector (Figure 7). Constitutive expression of *AdipoR1* or *AdipoR2* from the same multicopy vector resulted in a time- and concentration-dependent increase in Snf1p phosphorylation at Thr210 in response to osmotin or adiponectin treatments (Figures 7 and S8). These results demonstrated that AdipoR1 and AdipoR2 signaling in yeast and mammalian cells share an important common element, namely, the activation of AMPKα by phosphorylation. They also showed that IZH2 interferes with the AdipoR signaling that leads to Snf1p activation in *S. cerevisiae*.

**Osmotin-AdipoR Signaling Results in Suppression of Gene Expression via Stress Responsive Promoter Elements**

IZH2-mediated osmotin signaling activates the PKA pathway resulting in suppression of transcription from stress responsive promoter elements (STRE, 5′-CCCGT-3′). Mutation of IZH2 abrogates this effect [29] and conversely, overexpression of IZH2 suppresses transcription from STREs [26]. Accordingly, we observed that osmotin was unable to suppress STRE- lac expression in an izh2Δ mutant co-transformed with pSTRE-lac and p426-GPD vector (Figure 8). However, in an izh2Δ mutant co-transformed with pSTRE-lac and p426-GPD-AdipoR1 or p426-GPD-AdipoR2, STRE- lac expression was suppressed by osmotin treatment. Therefore AdipoR1 and AdipoR2 resemble IZH2 in their ability to activate ligand-dependent signaling via the PKA pathway in *S. cerevisiae*.

**Discussion**

We describe here a *S. cerevisiae* based system for investigating ligand/AdipoR1 interactions that lead to cellular signaling. The three-parts system consists of a split luciferase assay for reporting ligand-AdipoR1 interactions and assays to verify ligand-AdipoR mediated activation of Snf1p (yeast AMPKα) phosphorylation and PKA signaling pathways. Since adiponectin-AdipoR dependent activation of AMPKα phosphorylation and PKA signaling mediate anti-diabetic and cardioprotective effects of adiponectin, our *S. cerevisiae* based system has the potential to facilitate the discovery of AdipoR ligands with therapeutic value.

Besides osmotin and OSMpep [50], there are no known ligands of AdipoR1. Since osmotin and plant TLPs have similar structure and biological activity, and OSMpep is quite conserved between plant TLPs, we performed a comparative analysis of the binding of several homologs of OSMpep to membrane embedded AdipoR1 and were able to validate the ability of the split luciferase assay to discriminate between ligands based on the strength of their interactions.
binding to AdipoR1 (Figure 6 and Table 1). It should be noted that two biologically active adiponectin peptides that have been described [59,60] encompass residues that are predicted to interact with AdipoR1 by our model and by the earlier model (Figure S5) [50].

Split luciferase complementation assays have been successfully used to study protein-protein interactions in mammalian and plant systems but are used less frequently in S. cerevisiae. Our results show that they can be used to demonstrate protein-protein interactions in whole colonies of S. cerevisiae as well as in cells in liquid culture. We decided to base our assay for investigating ligand-AdipoR1 interactions on the first protein-protein interaction of AdipoR1 that is known to trigger downstream signaling underlying the anti-diabetic and cardioprotective effects of adiponectin, i.e. the interaction between AdipoRs and the coupling protein APPL1 (Figure 1) [43,53]. The split luciferase assay could possibly be optimized further by controlling relative expression levels of AdipoR1 and APPL1, for example, by expressing them from promoters regulated by different stimuli. In fact when the signal strengths in response to adiponectin are compared in 1%
galactose-grown *S. cerevisiae* cells transformed with pESC-URA-CLuc-AdipoR1-APPL1-NLuc, in which CLuc-AdipoR1 and APPL1-NLuc are expressed under the inducible GAL1 and GAL10 promoters on the high copy number p-ESC-URA vector (Figure 5) and in *S. cerevisiae* cells co-transformed with pESC-URA-CLuc-AdipoR1 and p425-GPD-APPL1-NLuc where the only difference is that APPL1-NLuc is expressed from the constitutive GPD promoter on the high copy number p425-GPD vector (Figure S9), the response to adiponectin is greater in the latter instance. Our preliminary results suggest that the split luciferase assay can be adopted for reporting ligand-AdipoR2 interactions (Figure S9). Therefore, with optimization and adaptation to robotic plating and washing, the split luciferase assay has the potential to be useful for screening chemical libraries for candidate AdipoR ligands.

APPL1 is a 709 amino acids protein that - ordered from the N- to the C-terminus - consists of BAR (Bin/Amphiphysin/Rvs), PH (plekstrin homology), BPP (between PH and PTB), PTB (phosphotyrosine binding) and CC (coiled coil) domains [54]. Sip3p is the closest structural relative of APPL1 in *S. cerevisiae*, consisting of 1229 amino acids and having only a PH domain (amino acids 310–423) in common with APPL1. Sip3p was identified as a transcriptional activator that interacts with DNA-bound Snf1p [55]. Inactivation of *SIP3* abrogates *IZH2* and AdipoR-dependent repression of *FET3* promoter activity in *S. cerevisiae* [26] (Figure 1). These data, and the fact that the PH domain of APPL1 which is known to mediate AMPK phosphorylation in mammalian cells [43] is conserved in Sip3p, led us to consider the possibility that Sip3p could interfere with the AdipoR1-APPL1 interaction. However, our results show that Sip3p does not interfere with the APPL1-AdipoR1 interaction.
responsive promoter elements. p426-GPD (Vec), p426-GPD-BWG1-7a

Figure 8. Osmotin signaling mediated by adiponectin receptors induces suppression of gene expression via stress responsive promoter elements. Cells (about 10^6/mL) of strain BWG1-7a, Izh2Δ::KanMX co-transformed with pSTRE-lacZLEU2) and p426-GPD (Vec), p426-GPD-AdipoR1 (pAdipoR1) or p426-GPD-AdipoR2 (pAdipoR2) were treated with osmotin (4 µM) in YPD for 45 min at 30°C and β-galactosidase activity was measured at the end of the treatment period. The values represent the means ± SE of two independent experiments with 3 to 4 samples per experiment.

doi:10.1371/journal.pone.0065454.g008

(4C). This is not surprising, since the overall homology between APPL1 and Sip3p is very low and Sip3p also lacks the PTB domain that mediates AdipoR1-APPL1 interaction. Overall, our results suggest that while Sip3p participates in the Snf1p PTB domain that mediates AdipoR1-APPL1 interaction. Overall, our results suggest that while Sip3p participates in the Snf1p PTB domain that mediates AdipoR1-APPL1 interaction. Overall, our results suggest that while Sip3p participates in the Snf1p PTB domain that mediates AdipoR1-APPL1 interaction.
inhibits AMPKα phosphorylation in the mammalian cells, it would appear as if both AdipoR1 and AdipoR2 contribute to osmotin activated AMPKα phosphorylation in the mammalian cells. There are possibly several other explanations for the discrepancy between the ability of AdipoR1 and AdipoR2 to contribute to osmotin-induced Snf1p phosphorylation in *S. cerevisiae* (Figure 7) and C2C12 myocytes [29]. Clearly our cell signaling assays can be improved when connections leading from ligand-AdipoRs to Snf1p phosphorylation and STRE-luc expression in *S. cerevisiae* are elucidated further.

Besides its use in the identification of new agonists of AdipoRs, the *S. cerevisiae* system described herein has potential for substantially increasing our understanding of ligand-AdipoR interactions and the resultant downstream signaling. For example, the split luciferase system can be used to screen a library of receptor mutants to delineate residues important for AdipoR-APPL1 interaction and AdipoR-ligand interactions. It should also be possible to identify residues of APPL1 that are necessary for AdipoR-APPL1 interaction by a similar approach. By screening a collection of *S. cerevisiae* mutants for inability to support the AdipoR1-APPL1 interaction, proteins required to stabilize this interaction can be discovered. Similarly, by transforming an expression library of mammalian cDNAs into *S. cerevisiae* having the CLuc-AdipoR/APPL1-NLuc constructs, it should be possible to identify mammalian proteins involved in stabilization/destabilization of the AdipoR-APPL1 complex. All of these studies will be greatly facilitated by our observation that the AdipoR-APPL1 interaction can be scored in *S. cerevisiae* colonies on plates. The basic understanding required to identify new pharmacologically valid targets and the identification of AdipoR ligands that can be facilitated by our *S. cerevisiae* assay system should have considerable value in discovery of therapeutic interventions for metabolic disorders.

Supporting Information

Figure S1 The AdipoR1 ligands, adiponectin and osmotin, induce increase in luciferase reporter activity. Cells of strain BY4741 carrying pESC-URA-CLuc-AdipoR1-APPL1-NLuc were grown for 16 h at 30°C in selective minimal medium at the indicated galactose concentrations, treated for 4 h at 30°C with the indicated test compounds and then assayed for luciferase activity. A representative image of relative luciferase activity with the different test compounds is shown for cells grown on 1% and 1.5% galactose. Luciferase (Luc) activities represent the means ± SD from three independent experiments with triplicate samples Symbols: PBS, 1/8 X PBS; OSM, 6.4 µM osmotin; f-ADPN, 2.8 µM bacterially expressed full length adiponectin; g-ADPN, 2.4 µM bacterially expressed globular adiponectin; f-ADPN*, 1.3 µM bacterially expressed full length adiponectin from a commercial source.

(TIF)

Figure S2 (A) Homology model of AdipoR1 embedded in membrane structure in preparation for molecular dynamics simulations. AdipoR1 is shown with orange color; DPPC membranes are shown with cyan color while water molecules are shown with O-red color and H-white color. (B) RMSD vs time after 50 ns of MD simulation at 300 K. The red curve indicates RMSD for Cα atoms and the black curve shows the RMSD for backbone atoms.

(TIF)

Figure S3 3D models of proteins and protein complexes used in this study. (A) Homology model of AdipoR1. Residues 355–374 are marked in yellow. These residues are not considered in the homology model developed by [49]. (B) Homology 3D-model of trimeric human globular adiponectin. The beta strands are indicated by arrows. Bound Ca²⁺ ions are shown as yellow spheres. (C) 3D-structure of osmotin (PDB id. 1PCV-chain A), (D) 3D model of the AdipoR1 binding site. Common residues of AdipoR1 interacting with both, adiponectin and osmotin are shown in blue. Residues interacting with adiponectin only are shown in red. (E) 3D model of the AdipoR1/activity with adiponectin and osmotin in the first, second and third top-scoring complexes.

(TIF)

Figure S4 Representation of AdipoR1 residues that interact with ligands used in this study. Interacting residues of AdipoR1 in the top-scoring complexes with adiponectin (ADPN), osmotin and the TLP peptides shown in Table 1 are shown. Interacting residues that were predicted by our model are shown in red font and interacting residues predicted by the model of [49] are shown in green font. C-terminal residues of AdipoR1 not included into the models are shown in gray font. P1, P2 and P3 represent the interactions of AdipoR1 with adiponectin and osmotin in the first, second and third top-scoring complexes.

(TIF)

Figure S5 Complete sequences of protein models used in this study. Shown in gray font are residues of the deduced amino acid sequences of all three proteins that were not used in the model. These include the N-terminal signal sequence of all the proteins, the intracellular N-terminal sequence of AdipoR1, the collagen domain of adiponectin and the C-terminal vacuolar targeting sequence of osmotin. Amino acids indicated by the red font represent the residues of AdipoR1 that interact with either adiponectin or osmotin, residues of adiponectin that interact with AdipoR1 and residues of osmotin that interact with AdipoR1, respectively. The OSMpep fragment (residues 157–165) is underlined and shown in bold.

(TIF)

Figure S6 Comparison of the binding of osmotin and OSMpep to AdipoR1. (A) Overlay of the three top scoring OSMpep poses (Green = best, purple = second, orange = third). (B) Overlay of the three top scoring OSMpep poses and osmotin (red).

(TIF)

Figure S7 Osmotin signaling mediated by adiponectin receptors does not induce Snf1p phosphorylation in wild type BWG1-7a cells. Cells (about 10⁷/mL) of strain BWG1-7a transformed with p426GPD (Vec), p426GPD-AdipoR1 (pAdipoR1) or p426GPD-AdipoR2 (pAdipoR2) were treated with osmotin and adiponectin at 30°C in YPD. Aliquots were withdrawn for viable counts determination before the cell lysates were prepared for analysis by 10% SDS-PAGE, 100 µg total proteins were loaded per lane. (A) Time dependent changes in Snf1p phosphorylation with osmotin (0.5 µM) or adiponectin (0.5 µM). Shown are blots probed first with phospho-AMPK(Thr-172) antibody, then stripped and probed with actin antibody. (B,C) Osmotin and adiponectin concentration dependent changes in Snf1p phosphorylation. Treatment time was 30 min. Shown in the top panels are blots probed first with phospho-AMPK(Thr-172) antibody, then stripped and probed with actin antibody. Shown in the middle panels are relative band intensities in the depicted gels. ‘Relative band intensity’ was defined as the ratio of the
intensity of phospho-Snf1p signal to actin signal for each lane when the value of this ratio for the corresponding untreated Vec sample was arbitrarily assigned the value 1.0. Shown in the bottom panels are viable counts in each sample at the end of the treatments. The experiments were performed twice with comparable results and the results of one experiment are shown.

**Figure S8** Time dependent increase in Snf1 phosphorylation in *izh2* mutant in response to osmotin or adiponectin treatment. Cells (about 10^7/mL) of strain BWG1-7a transformed with p426GPD (Vec), p426GPD-AdipoR1 (pAdipoR1) or p426GPD-AdipoR2 (pAdipoR2) were treated with osmotin (0.5 μM) or adiponectin (0.5 μM) at 30°C in YPD for the indicated times. Shown are blots of total protein extracts fractionated by 10% SDS-PAGE that were probed first with phospho-AMPK (Thr-172) antibody, then stripped and probed with actin antibody. 100 μg total proteins were loaded per lane.

**Figure S9** Luciferase reporter activity depends on the expression level of receptor at a constant level of APPL1. (A) RT-PCR analysis of AdipoR1 and APPL1 expression in total RNA (2 μg) from cells of strain BY4741 carrying indicated plasmids that were grown for 16 h at 30°C in selective minimal medium containing 2% galactose. ACT1 expression is shown for normalization. (B-D) Quantification of luciferase activity in BY4741 cells carrying indicated plasmids. Cells were grown for 16 h at 30°C in selective minimal medium at the indicated galactose concentrations. The final concentration of sugars in all media was adjusted to 2% with raffinose. Shown is quantification of luciferase activity. Inset is a representative image of the microplate (showing from left, cells grown in 0, 0.25, 0.5, 1, 1.5, and 2% galactose). (E) Adiponectin stimulates luciferase activity. Cells of strain BY4741 carrying p425GPD-APPL1-NLuc and either pESC-URA-CLuc-AdipoR1 or pESC-URA-CLuc-AdipoR2 were grown for 16 h at 30°C in selective minimal medium at the indicated galactose concentrations, treated for 2 h at 30°C with 1/10 X PBS (−) or full length bacterially expressed adiponectin (+). Luciferase activity was then visualized by imaging.

**Table S1** Primers used for construction of plasmids.

**Table S2** Primers used for gene expression analysis by RT-PCR.

**Methods S1**

**Acknowledgments**

We thank Drs. Irina Sokolchik (Purdue University, USA) and Aftabadrul Shaerkhau (KAUST, Saudi Arabia) for their gifts of adiponectin and for help with osmotin preparation. We are grateful to Dr. S. Lu (KAUST, Saudi Arabia) for his suggestion to use luciferase as the reporter for protein-protein interaction and Dr. D. Ramotar (University of Montreal/Montreal, QC) for providing the BY4741 yeast strain.

**Author Contributions**

Conceived and designed the experiments: MA KK ARS. Performed the experiments: MA KK ARS. Analyzed the data: MA ARS. Contributed reagents/materials/analysis tools: JE DJY RAB JMP MA. Wrote the paper: MLN MA JE ARS.

**References**

1. Berg AH, Combs TP, Scherer PE (2002) ACR30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13: 84–89.
2. Jortar J, Senou M, Abou-Samra M, Noel L, Robert A, et al. (2012) Adiponectin and skeletal muscle: pathophysiological implications in metabolic stress. Am J Physiol 290: 1723–1729.
3. Kadwadi T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439–451.
4. Fang Y, Lau BW, Guo E, Tao L, Yuan Y, et al. (2010) Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 298: E663–670.
5. Harahara K, Hirai H, Katsumi N, Kitajima A, Hara M, et al. (2007) Expression of adiponectin in human adipose tissue: relationship with insulin resistance and metabolic syndrome. Diabetes 56: 536–540.
6. Kontos H, Shimomura I, Matsukawa Y, Kuida K, Takahashi M, et al. (2002) Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51: 2325–2328.
7. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33: 547–594.
8. Matsuzawa Y (2010) Adiponectin: a key player in obesity related disorders. Curr Pharm Des 16: 1906–1916.
9. Ohashi K, Ouchi N, Matsuzawa Y (2011) Adiponectin and hypertension. Curr Hypertens Rep 13: 263–269.
10. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947–953.
11. Ishikawa M, Kitayama J, Yamauchi T, Kadwadi T, Maki T, et al. (2007) Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 98: 1120–1127.
12. Matsuda M, Shimaomura I, Sata M, Arita Y, Nishida M, et al. (2002) Role of adiponectin in preventing vascular senescence. The missing link of adiposity and prevention of atherosclerosis. J Biol Chem 277: 37487–37491.
13. Moun HS, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, et al. (2012) Subcutaneous inflammation of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut.
14. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, et al. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11: 1120–1127.
15. Shklyaev S, Aslandi G, Tannant M, Prima V, Kohlhermer E, et al. (2003) Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci U S A 100: 14217–14222.
16. Yamauchi T, Kamon J, Waki H, Terazaki Y, Kubota N, et al. (2003) The fatty-derived hormone adiponectin reverses insulin resistance associated with both hepatosteatosis and obesity. Nat Med 9: 941–946.
17. Yamauchi T, Ninomiya Y, Miki T, Kobayashi M, Takazawa T, et al. (2004) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 10: 332–339.
18. Tang YT, Hu T, Arterburn M, Boyle B, Bright JM, et al. (2005) PAQR proteins: a novel membrane receptor family defined by an ancient 7-transmembrane pass motif. J Mol Biol 351: 372–380.
19. Fang X, Sweeney G (2006) Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem Soc Trans 34: 798–801.
20. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, et al. (2010) Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+)-and AMPK/SIRT1. Nature 464: 1313–1319.
21. Yamauchi T, Kamon J, Iyo Y, Tsuda R, Yokomizo T, et al. (2003) Cloning of adiponectin receptors that mediate anti-diabetic metabolic effects. Nature 423: 762–769.
22. Goldstein BJ, Scalla RG, Ma XL (2009) Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 6: 27–35.
23. Petranoic D, Tyo K, Venniri GN, Nielsen J (2010) Prospects of yeast systems biology for human health: integrating lipid, protein and energy metabolism. FEMS Yeast Res 10: 1046–1059.
24. Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25: 1893–1900.
25. Hoeflacker K, Carlson M (2008) SNF1/AMPK pathways in yeast. Front Biosci 13: 2496–2490.
26. Kupchak BR, Garitaonanda I, Villa NY, Muller MB, Weaver MG, et al. (2007) Probing the mechanism of FET3 repression by Izh2p overexpression. Biochem Biophys Acta 1773: 1124–1132.
27. Kupchak BR, Villa NY, Kulemina LV, Lyons TJ (2008) Dissecting the role of yeast genes by the osmotin receptor. Biochem Biophys Res Commun 357: 210–213.
28. Jamieson DJ (1998) Oxidative stress responses of the yeast Saccharomyces cerevisiae. Yeast 14: 1511–1527.
29. Narasimhan ML, Coca MA, Jin J, Yamauchi T, Iyo Y, et al. (2003) Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17: 171–180.
30. Becker DM, Guarente L (1991) High-efficiency transformation of yeast by electroporation. Method Enzymol 194: 182–187.

31. Gietz RD, Schiestl RH (2007) Large-scale high-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc 2: 30–41.

32. Wach A, Brachet A, Pohlmann R, Philippen P (1994) New heterologous modules for classical or PCR-based gene disruptions in Saccharomyces cerevisiae. Yeast 10: 1795–1800.

33. Chen H, Zou Y, Shang Y, Liu H, Wang Y, et al. (2008) Firefly luciferase complementation imaging assay for protein-protein interactions in plants. Plant Physiol 146: 368–376.

34. Narasimhan ML, Damuz B, Coca MA, Ibrea JI, Yun DJ, et al. (2001) A plant defense response effector induces microbial apoptosis. Mol Cell B 8: 921–930.

35. Lee H, Damuz B, Woloshuk CP, Bressan RA, Narasimhan ML (2010) Use of the plant defense protein osmotin to identify Fusarium oxysporum genes that control cell wall properties. Eukaryot Cell 9: 558–568.

36. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, et al. (2006) Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochim Biophys Acta 1763: 271–279.

37. Neumeier M, Weigert J, Schaffer A, Wehrwein G, Muller-Ladner U, et al. (2006) Different effects of adiponectin isoforms in human monocytes cells. J Leukoc Biol 79: 803–808.

38. Masson JY, Ramotar D (1997) Normal processing of AP sites in Apn1-deficient Saccharomyces cerevisiae is restored by Escherichia coli genes expressing either exonuclease III or endonuclease III. Mol Microbiol 24: 711–721.

39. Edman K, Royant A, Nollert P, Maxwell CA, Pebay-Peyroula E, et al. (2002) Analysis of the SIP3 protein identified in a two-hybrid screen for interaction with the SNF1 protein kinase. Nucleic Acids Res 22: 977–983.

40. Min K, Ha SC, Hasegawa PM, Bressan RA, Yun DJ, et al. (2004) Crystal structure of an algal peroxidase. J Biol Chem 279: 16359–16362.

41. Krieger E, Koraimann G, Vriend G (2002) Increasing the precision of comparative models with YASARA NOVA—a self-parameterizing force field. Proteins 47: 393–402.

42. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235–242.

43. Oostenbrink C, Villa A, Mark AE, van Gunsteren WF (2004) A biomolecular force-field parameter set 53A5 for human immunoglobulin G. J Comput Chem 25: 1656–1676.

44. Zhou L, Deepa SS, Etzler JC, Ryu J, Mao X, et al. (2009) Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem 284: 22426–22435.

45. Fujikawa Y, Kato N (2007) Split luciferase complementation assay to study protein-protein interactions in Arabidopsis protoplasts. Plant J 52: 183–195.

46. Lou Y, Shanklin J (2010) Evidence that the yeast desaturase Ole1p exists as a dimer in vivo. J Biol Chem 285: 19384–19390.

47. Paulmurugan R, Gambhir SS (2005) Firefly luciferase enzyme fragment complementation for imaging in cells and living animals. Anal Chem 77: 1295–1302.

48. Villa NY, Kupchak BR, Garaionaandia I, Smith JL, Alonso E, et al. (2009) Sphingolipids function as downstream effectors of a fungal PAQR. Mol Pharmacol 75: 866–875.

49. Miele M, Costantini S, Colonna G (2011) Structural and functional similarities between osmotin from Nicotiana tabacum seeds and human adiponectin. PLoS One 6: e16689.

50. Garaionaandia I, Smith JL, Kupchak BR, Lyons TJ (2009) Adiponectin identified as an agonist for PAQR3/RKTG using a yeast-based assay system. J Recept Signal Transduct Res 29: 67–73.

51. Veronese P, Ruiz MT, Coca MA, Hernandez-Lopez A, Lee H, et al. (2003) In defense against pathogens. Both plant sentinel and foot soldiers need to know the enemy. Plant Physiol 131: 1580–1590.

52. Min X, Lemon B, Tang J, Liu Q, Zhang R, et al. (2012) Crystal structure of a single-chain trimer of human adiponectin globular domain. FEBS Lett 586: 912–917.

53. Fang WL, Zhou B, Wang YY, Chen Y, Zhang L (2010) Analysis of adiponectin gene polymorphisms in Chinese population with systemic lupus erythematosus. J Biomed Biotechnol 2010: 401537.

54. Deepa SS, Dong LQ (2009) APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 296: 32–36.

55. Lesage P, Menu-Bouaouiche L, Peumans WJ, Payan F, Barre A, et al. (2006) Resolution of the structure of the allergenic and antifungal banana fruit thaumatin-like protein at 1.7-Å. Biochimie 88: 45–52.

56. Ko TP, Day J, Greenwood A, McPherson A (1994) Structures of three crystal forms of the sweet protein thaumatin. Acta Crystallogr D Biol Crystallogr 50: 813–825.

57. Palacin A, Rodriguez J, Blanco C, Lopez-Torrejon G, Sanchez-Monge R, et al. (2006) Immunoglobulin E recognition patterns to purified Kiwifruit (Actinidia delicosa) allergens in patients sensitized to Kiwi with different clinical symptoms. Clin Exp Allergy 36: 1220–1228.

58. Batalia MA, Monzingo AF, Ernst S, Roberts W, Roberuts JD (1996) The crystal structure of the antifungal protein zeamatin, a member of the thaumatin-like, PR-5 protein family. Nat Struct Biol 3: 19–25.